Real-world performance of indobufen versus aspirin after percutaneous coronary intervention: insights from the ASPIRATION registry

Chunfeng Dai,Muyin Liu,Zheng Yang,Youran Li,You Zhou,Danbo Lu,Yan Xia,Ao Chen,Chenguang Li,Hao Lu,Yuxiang Dai,Jianying Ma,Zhangwei Chen,Juying Qian and Junbo Ge

DOI: https://doi.org/10.1186/s12916-024-03374-3

IF: 9.3

2024-04-04

BMC Medicine

Abstract:Indobufen is widely used in patients with aspirin intolerance in East Asia. The OPTION trial launched by our cardiac center examined the performance of indobufen based dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI). However, the vast majority of patients with acute coronary syndrome (ACS) and aspirin intolerance were excluded. We aimed to explore this question in a real-world population.

medicine, general & internal